Skip to content
HowShorted

Allogene Therapeutics, Inc. short interest in 2020

In 2020, Allogene Therapeutics, Inc.'s disclosed short interest ran from 10.69% of shares outstanding on 15 Jan 2020 to 9.29% on 31 Dec 2020, a change of -1.40 percentage points. The year's high was 11.58% on 15 Apr 2020 and its low 7.23% on 30 Oct 2020, averaging 9.30% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 32.57 days on 14 Feb 2020. Full history: Allogene Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Allogene Therapeutics, Inc. in 2020

2020 in figures

Start of year
10.69% (15 Jan 2020)
End of year
9.29% (31 Dec 2020)
Change
-1.40 pp
High
11.58% (15 Apr 2020)
Low
7.23% (30 Oct 2020)
Average
9.30%
Highest days to cover
32.57 (14 Feb 2020)
SEC filings marked
8

Every report in 2020

Allogene Therapeutics, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202010.69%29.65
31 Jan 202010.54%22.69
14 Feb 202010.68%32.57
28 Feb 202010.62%16.1810-K filed, results (8-K)
13 Mar 202010.86%16.69
31 Mar 202010.83%19.87
15 Apr 202011.58%22.67
30 Apr 202010.80%20.57
15 May 202010.74%8.6410-Q filed, results (8-K)
29 May 202010.57%13.28
15 Jun 20209.17%6.82
30 Jun 202010.71%15.34
15 Jul 20209.62%19.54
31 Jul 20208.78%27.34
14 Aug 20207.68%18.3910-Q filed, results (8-K)
31 Aug 20207.72%21.61
15 Sep 20207.33%23.39
30 Sep 20207.44%15.55
15 Oct 20207.26%19.37
30 Oct 20207.23%23.21
13 Nov 20207.55%9.7710-Q filed, results (8-K)
30 Nov 20207.59%16.17
15 Dec 20208.03%11.34
31 Dec 20209.29%14.38

See also: Allogene Therapeutics, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.